Chris Ryan | Authors


Frontline Pembrolizumab Noninferior But Not Superior to Frontline Chemo in PD-L1+ Gastric/GEJ Adenocarcinoma

January 21, 2022

Results from the phase 3 KEYNOTE-062 study appear mixed for both pembrolizumab monotherapy versus chemotherapy and pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Cilta-cel Demonstrates Significant Advantage Over SOC in Triple-Class R/R Myeloma

December 13, 2021

A CARTITUDE-1 meta-analysis data shows that ciltacabtagene autoleucel performs better than standard-of-care therapy in terms of survival and response rates in patients with triple-class relapsed/refractory multiple myeloma.